BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, effective immediately. “Jane has worked with Vera Therapeutics previously as a strategic legal consultant and brings a depth and breadth of experience in supporting companies throu ...

On February 17, 2026, Integral Health Asset Management disclosed a buy of 100,000 Vera Therapeutics (NASDAQ:VERA) shares, an estimated $3.55 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Integral Health Asset Management increased its position in Vera Therapeutics by 100,000 shares. The estimated value of this trade, based on the average closing price for the quarter ending December 31, 2025, is $3.55 ...

Deerfield Management Company disclosed a buy of 418,538 shares of Vera Therapeutics (NASDAQ:VERA) in its February 17, 2026, SEC filing, with an estimated transaction value of $14.87 million based on the quarter’s average price. What happened According to a recent SEC filing, Deerfield Management Company increased its holding in Vera Therapeutics (NASDAQ:VERA) by 418,538 shares during the fourth quarter of 2025. The estimated transaction value, calculated using the period’s average closing price, was appr ...

Core Viewpoint - Vera Therapeutics, Inc. has granted inducement awards to six new employees, consisting of stock options and restricted stock units (RSUs), as part of its 2024 Inducement Plan [1][2]. Group 1: Inducement Awards - The Compensation Committee approved the grant of non-qualified stock options to purchase 46,000 shares of Class A common stock and RSUs for 25,875 shares of Class A common stock [1]. - The stock options have an exercise price of $39.30, which is the closing trading price on March 3, 2026 [2]. - The vesting schedule for stock options includes 25% vesting on the first anniversary, with the remaining shares vesting monthly over the next 36 months, contingent on continued service [2]. Group 2: Vesting Conditions - RSUs will also vest over four years, with 25% vesting on each anniversary of either February 20 or May 20, 2026, depending on the new employee's start date [2]. - Both stock options and RSUs are subject to the terms of the Inducement Plan and applicable award agreements [2].

Group 1 - The FDA is currently reviewing the atacicept application submitted by the company, which has been accepted with a PDUFA date set for July 7, indicating a priority review status [2] - The data package for the atacicept application appears to be straightforward, suggesting that there may not be significant issues to address during the mid-cycle review [2] - Discussion points for potential FDA focus include labeling and other review issues, indicating that the company is preparing for possible inquiries from the FDA [2]

Core Insights - Vera Therapeutics, Inc. has appointed Christopher Hite to its Board of Directors, bringing extensive experience in corporate and financial strategy within the biopharmaceutical sector [1][2] - The company is nearing the potential launch of its first-in-class dual BAFF/APRIL inhibitor, atacicept, aimed at treating IgA nephropathy [2] Company Overview - Vera Therapeutics is focused on developing transformative treatments for serious immunological diseases, with a mission to change the standard of care for patients [3] - The lead product candidate, atacicept, is a fusion protein administered as a subcutaneous injection once a week, targeting B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) to reduce autoantibody production [3] - The company holds an exclusive license for a next-generation fusion protein, VT-109, and is also developing MAU868, a monoclonal antibody for BK virus infections in kidney transplant recipients [3]

Summary of Vera Therapeutics FY Conference Call Company Overview - **Company**: Vera Therapeutics (NasdaqGM:VERA) - **Focus**: Development of atacicept for IgA nephropathy (IgAN) Key Points FDA Review and PDUFA Date - The FDA has accepted the atacicept application with a PDUFA date set for **July 7, 2026** [1] - The review process is described as straightforward, with no major issues anticipated [2][4] - Label negotiations will occur later in the review cycle, with expectations for a broad indication similar to Otsuka's recent approval for Voyxact [5][10] Clinical Data and Efficacy - Atacicept shows a transformative GFR profile with a slope of **-0.6** at two years, a result not previously seen in IgAN treatments [18] - The focus is shifting from proteinuria to GFR as a key efficacy measure, reflecting a new understanding of at-risk IgAN patients [20][12] - There are approximately **160,000** prevalent IgAN patients in the U.S., with an estimated **80,000** at risk of rapid progression [108] Market Opportunity and Competition - The majority of the market opportunity is in the U.S., particularly among young patients with commercial insurance [35] - Early signs of demand are noted, with Otsuka reporting **500 patient start forms** in the first 11 weeks of Voyxact's launch [45] - Vera plans to position atacicept competitively against existing therapies, emphasizing a patient-friendly auto-injector with a once-weekly dosing schedule [60][62] Commercial Strategy - The sales force is fully hired and will be trained three months prior to launch, focusing on disease state education and patient identification [71][75] - The company has conducted over **20 PIE presentations** with payers to prepare for market access and reimbursement [130] - The distribution model will primarily utilize specialty pharmacies, with a focus on maintaining a favorable gross-to-net ratio due to high commercial pay [146][153] Regulatory and International Considerations - Vera has a global regulatory presence and is making progress in discussions for markets outside the U.S., including Europe and Japan [179] - There is a higher prevalence of IgAN in East Asian countries, with estimates of **3 million to 5 million** patients in China [188] Pipeline and Future Developments - Vera is also developing a monthly dosing regimen for atacicept, with ongoing studies to determine the appropriate endpoints [194][196] - The company has a new pipeline candidate, VT-109, which may enable longer dosing intervals, potentially quarterly or biannually [221][224] Intellectual Property - Vera has established a robust IP portfolio to protect its products, with exclusivity extending to **2047** [212][215] Additional Insights - The company is focused on providing a comprehensive patient support system to ensure adherence and access to treatment [157][166] - The competitive landscape is evolving, with a strong emphasis on safety and efficacy as key differentiators in the market [176][178] This summary encapsulates the critical insights from the conference call, highlighting Vera Therapeutics' strategic positioning, market opportunities, and ongoing developments in the context of its lead product, atacicept.

Financial Position - As of December 31, 2025, the company had $714.6 million in cash, cash equivalents, and marketable securities, expected to fund operations beyond the next 12 months [303]. - The company incurred net losses of $299.6 million, $152.1 million, and $96.0 million for the fiscal years ended December 31, 2025, 2024, and 2023, respectively, with an accumulated deficit of $760.9 million as of December 31, 2025 [306]. - The company entered into a Loan and Security Agreement in June 2025 with a borrowing capacity of up to $500.0 million, with an outstanding debt balance of $75.0 million as of December 31, 2025 [312]. - The company has federal net operating loss (NOL) carryforwards of $389.9 million and state NOL carryforwards of $42.3 million, with $10.2 million of federal NOLs and $37.0 million of state NOLs beginning to expire in 2032 and 2036, respectively [460]. - The company may face limitations on utilizing its NOLs due to potential "ownership changes," which could adversely affect cash flows and operational results [461]. Revenue Generation and Commercialization - The company has no products approved for commercial sale and has not generated any revenue from product sales to date [300]. - The company anticipates significant commercialization expenses related to drug sales, marketing, manufacturing, and distribution if marketing approval is obtained for product candidates [311]. - The company expects to continue incurring increased expenses and operating losses for the foreseeable future as it seeks regulatory approval for its product candidates [307]. - The successful commercialization of product candidates will depend on obtaining adequate coverage and reimbursement from governmental authorities and third-party payors [392]. - The company faces significant uncertainty regarding third-party payor coverage and reimbursement for newly approved products, which can impact sales revenue [394]. Regulatory and Approval Challenges - The company is substantially dependent on the success of its product candidates and must complete clinical trials and obtain regulatory approval to commercialize them [314]. - Regulatory approval processes are lengthy and unpredictable, potentially harming the company's business and financial condition if approvals are not obtained [349]. - The approval policies of regulatory authorities may change, potentially impacting the company's ability to obtain marketing approval for its product candidates [322]. - The company may face delays or rejections of product approvals, which could inhibit its ability to generate revenue [370]. - The FDA's policies may change, potentially delaying regulatory approval of product candidates, impacting the company's financial condition and prospects [368]. Clinical Development Risks - Delays in clinical trials are common and can jeopardize regulatory approval and product sales, potentially increasing costs [323][325]. - The company may face challenges in enrolling and retaining participants in clinical trials, which could result in significant delays and increased costs [329][330]. - The company may need to conduct additional trials if initial results are not satisfactory to regulatory authorities, leading to increased resource expenditure [322][326]. - Interim and preliminary data from clinical trials may change as more data becomes available, which could impact the company's business prospects [337][340]. Competitive Landscape - The biotechnology industry is highly competitive, with significant competition from multinational pharmaceutical companies and specialized biotechnology firms [341]. - Competitors possess significantly greater financial, technical, and human resources, which may enhance their ability to develop and market superior products [345]. - The market opportunities for the company's product candidates may be smaller than estimated, affecting revenue and profitability [336]. Intellectual Property and Legal Risks - The company relies on its ability to protect intellectual property, with risks including potential invalidation of patents and challenges in maintaining licensing agreements [464][477]. - The patent application process is complex and costly, with uncertainties that could hinder the company's ability to protect its intellectual property effectively [470]. - The company’s commercial success depends on avoiding infringement of third-party patents, and claims of infringement could result in significant liability for damages [493]. - The biotechnology industry is experiencing increased patent litigation, which could limit the company's ability to commercialize its product candidates [496]. Compliance and Regulatory Obligations - The company faces ongoing substantial costs to ensure compliance with healthcare laws and regulations, which may lead to significant penalties if violations occur [419]. - The company is subject to stringent data privacy and security laws, which could result in regulatory investigations, litigation, and fines if compliance is perceived to be lacking [420]. - Compliance with evolving regulations, such as the EU Clinical Trials Regulation, may require substantial resources and impact development plans [409]. - The company may incur significant costs to comply with environmental, health, and safety laws, which could impair research and development efforts [431]. Market and Economic Factors - Future healthcare reform legislation may increase the difficulty and cost of commercializing product candidates, negatively impacting business operations [399]. - The ongoing military conflict between Ukraine and Russia has introduced significant uncertainty into global markets, potentially disrupting trade and credit availability [441]. - Elevated inflation rates in the U.S. could increase operating costs and limit access to credit, adversely affecting the company's financial condition [440].

Financial Performance - Vera Therapeutics reported a net loss of $299.6 million for the year ended December 31, 2025, compared to a net loss of $152.1 million in 2024, representing a 96.8% increase in losses year-over-year[8] - Total operating expenses for 2025 were $315.5 million, up from $167.2 million in 2024, indicating an increase of 88.6%[20] - Research and development expenses for 2025 were $215.3 million, compared to $126.2 million in 2024, reflecting a 70.6% increase[20] Cash and Financing - The company had cash, cash equivalents, and marketable securities totaling $714.6 million as of December 31, 2025, an increase from $640.9 million in 2024[9] - Vera Therapeutics completed an equity financing and entered into a debt agreement, resulting in combined potential gross proceeds of $800 million to strengthen its balance sheet[12] Regulatory and Clinical Developments - The FDA granted priority review for the Biologics License Application (BLA) for atacicept, with a Prescription Drug User Fee Act (PDUFA) date set for July 7, 2026, and a potential commercial launch expected in mid-2026[6] - Positive Phase 3 data from the ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) demonstrated clinically meaningful reductions in proteinuria and stabilization of eGFR[6] - The company plans to release initial results from the PIONEER Phase 2 trial evaluating atacicept in expanded IgAN populations in the first half of 2026[12] - The ORIGIN Phase 3 trial met its primary endpoint with a statistically significant reduction in proteinuria at week 36[13] Leadership Changes - Vera Therapeutics appointed James R. Meyers to its Board of Directors, bringing over three decades of commercial leadership experience[12]

Core Insights - Vera Therapeutics is advancing its lead product candidate, atacicept, towards potential FDA approval and commercialization, with a priority review granted for its Biologics License Application (BLA) [2][6][7] - The company reported a significant increase in net loss for the year ended December 31, 2025, amounting to $299.6 million, compared to a net loss of $152.1 million in 2024 [5][17] - Vera Therapeutics has a strong financial position with $714.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which is expected to fund operations beyond the anticipated approval and U.S. commercial launch of atacicept [8][18] Business Highlights - In 2025, Vera Therapeutics achieved key milestones, including positive Phase 3 data from the ORIGIN study of atacicept in IgA nephropathy (IgAN) and the establishment of a leadership position in the IgAN space [2][6][10] - The ORIGIN Phase 3 trial met its primary endpoint with a statistically significant reduction in proteinuria, and the safety profile of atacicept was comparable to placebo [11][12] - The company appointed James R. Meyers to its Board of Directors, bringing over three decades of commercial leadership experience [7] Financial Results - For the year ended December 31, 2025, total operating expenses were $315.5 million, up from $167.2 million in 2024, with research and development expenses increasing to $215.3 million [17] - The net loss per diluted share increased to $4.66 in 2025 from $2.75 in 2024 [5][17] - Cash used in operating activities rose to $241.1 million in 2025, compared to $134.7 million in 2024 [8] Upcoming Milestones - The FDA has set a PDUFA date of July 7, 2026, for the atacicept BLA, with a potential commercial launch expected in mid-2026 [6][7] - Initial results from the PIONEER Phase 2 trial, evaluating atacicept in expanded IgAN populations and other autoimmune kidney diseases, are anticipated in the first half of 2026 [7] - Completion of the ORIGIN 3 study with two-year eGFR data is expected in 2027 [7]